Navigation Links
Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Date:9/11/2008

clinical trial and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, and have completed a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it for clinical development.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward- looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events th
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
11. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 About POCT ... performed outside a clinical laboratory. It helps in ... appropriate treatments and medication. POCT is gaining popularity ... lifestyle diseases such as diabetes, heart disease, and ... devices are standardized to minimize errors during the ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... an exclusive license for technology developed by the ... expression in plants, including for applications in production of ... The technology was developed under the direction of ... Kultevat and former president of the Danforth Plant Science ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 2
... KBI Biopharma, Inc. (KBI) announced today that it ... with Crucell,s PER.C6(R) human cell line platform, pursuant to ... 6, 2009. Under that agreement, KBI joins the Vendor ... for licensees of the PER.C6(R) cell lines. , ...
... International Products Corporation,s ( http://www.ipcol.com ) ... membrane compatibility and performance studies using a versatile ... any type of membrane media, from UF to RO, and ... "Our goal is to be able to recommend the most ...
... Release Highlights, - Melogliptin continues to demonstrate potential to ... low incidence of, hypoglycemia and neutral effect on ... by end 2009, - IND approved by USFDA, ... Indian company to have a truly global innovative drug for ...
Cached Biology Technology:KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R) 2International Products Corp.'s Lab Offers Filter Membrane Compatibility and Studies 2Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/18/2014)... A new GSA Bulletin study uses ... Rio Puerco and Chaco Wash in northern New Mexico, ... salt cedar and willow, investigators were able to precisely ... They then combined this data with aerial imagery, LiDAR, ... of these arroyos. , Arroyos are deep, oversized channels ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... as to how HIV evades the human immune system ... The findings suggest some HIV vaccines may have failed ... patient's own immune system is programmed to destroy. , ... which recognize and latch onto the HIV protein gp41, ...
... Africa, where days of heavy rains and flooding have led ... are reporting an unprecedented rise in Somalia's Shabelle River and ... centre of the country, the United Nations said today. , ... Affairs (OCHA), reports yesterday from Belet Weyne, close to the ...
... to recover in adolescent females once they stop using ... a study funded by the National Institute of Child ... Health. , Previous studies had shown that women who ... a loss of bone mineral density during the time ...
Cached Biology News:New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines 2New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines 3Bone Density Recovers After Teens Stop Injected Contraceptive 2Bone Density Recovers After Teens Stop Injected Contraceptive 3
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... for calibrating single-channel and multi-channel pipettes. ,Thanks ... carrying case, the MCP1-S is ideal for ... on-site at the users premises. The unit ... individual channels are tested automatically. Multi-channel pipettes ...
... ChIP-on-chip Microarray is specifically designed for ... DNA binding proteins by pairing chromatin ... This set delivers robust hybridization and ... binding events and fewer false positives. ...
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
Biology Products: